Iuorno v. Dupont Pharmaceuticals Co.

129 F. App'x 637
CourtCourt of Appeals for the Second Circuit
DecidedJanuary 31, 2005
DocketNo. 04-2049
StatusPublished
Cited by2 cases

This text of 129 F. App'x 637 (Iuorno v. Dupont Pharmaceuticals Co.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Second Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Iuorno v. Dupont Pharmaceuticals Co., 129 F. App'x 637 (2d Cir. 2005).

Opinion

[639]*639SUMMARY ORDER

Plaintiff-appellant Jaoquina Iuorno, a sixty-two-year-old native of the Philippines, submits that the district court erred in awarding summary judgment to defendant-appellee DuPont Pharmaceuticals Company (“DuPont”)2 on her claims of employment discrimination based on race and national origin in violation of Title VII of the Civil Rights Act of 1964 (“Title VII”), 42 U.S.C. §§ 2000e-2 — 2000e-17, and 42 U.S.C. § 1981, and also based on age in violation of the Age Discrimination in Employment Act (“ADEA”), 29 U.S.C. §§ 621-634.3 We assume the parties’ familiarity with the facts and the record of proceedings, which we reference only as necessary to explain our decision.

We review an award of summary judgment de novo, and we will affirm only if the record, viewed in the light most favorable to the non-moving party, reveals “no genuine issue as to any material fact” but supports a conclusion that “the moving party is entitled to a judgment as a matter of law.” Fed.R.Civ.P. 56(c); see Terry v. Ashcroft, 336 F.3d 128, 137 (2d Cir.2003) (and cases cited therein).

Motions for summary judgment on federal employment discrimination claims are generally reviewed pursuant to the three-step burden-shifting analysis set forth in McDonnell Douglas Corp. v. Green, 411 U.S. 792, 802-05, 93 S.Ct. 1817, 36 L.Ed.2d 668 (1973). See St. Mary’s Honor Ctr. v. Hicks, 509 U.S. 502, 506-08, 113 S.Ct. 2742, 125 L.Ed.2d 407 (1993) (Title VII); Patterson v. McLean Credit Union, 491 U.S. 164, 186, 109 S.Ct. 2363, 105 L.Ed.2d 132 (1989) (§ 1981);4 Terry v. Ashcroft, 336 F.3d at 138 (ADEA). Although DuPont disputes the district court’s conclusion that Iuorno satisfied the “de minimis” first step of establishing a prima facie case, see Abdu v. Brisson v. Delta Air Lines, Inc., 239 F.3d 456, 467 (2d Cir.2001), we need not address that argument because we conclude, as did the district court, that Iuorno’s case fails at the third step, i.e., the record as a whole would not permit plaintiff, as a matter of law, to satisfy her “ultimate burden of persuading the trier of fact that the defendant intentionally discriminated” against her based on race, national origin, or age, Reeves v. Sanderson Plumbing Prods., Inc., 530 U.S. 133, 143, 120 S.Ct. 2097, 147 L.Ed.2d 105 (2000) (quoting Texas Dep’t of Cmty. Affairs v. Burdine, 450 U.S. 248, 253, 101 S.Ct. 1089, 67 L.Ed.2d 207 (1981)); see Terry v. Ashcroft, 336 F.3d at 138; Lizardo v. Denny’s, Inc., 270 F.3d 94, 103 (2d Cir.2001); [640]*640Schnabel v. Abramson, 232 F.3d 83, 90 (2d Cir.2000).

DuPont asserts that it terminated Iuorno for a non-discriminatory reason; specifically, in September 2000, while working as a chemist in the company’s Finished Products pharmaceutical laboratory, Iuorno committed numerous, serious violations of both the company’s standard operating procedures and regulations mandated by the Food and Drug Administration (“FDA”). Although Iuorno conclusorily dismisses these violations as harmless, the record plainly evidences the legitimacy of her employer’s concern. See Dister v. Conti Group, Inc. 859 F.2d 1108, 1116 (2d Cir.1988) (noting that “it is not the function of a fact-finder to second-guess business decisions or to question a corporation’s means to achieve a legitimate goal”). On two separate occasions in mid-September 2000, Iuorno violated operating procedures and FDA regulations mandating that all chemists’ test calculations be recorded when performed and only in preserialized, bound laboratory notebooks with consecutively numbered pages. Plainly, the purpose of the procedure is to ensure the integrity and completeness of test data in this regulated industry. Instead of following the procedure, Iuorno noted her test results in a personal notebook, intending to transfer these entries to an official notebook on some future date, an express violation of rules against backdating. As a result of this conduct, Iuorno also violated a related operating procedure, requiring one chemist to provide another with transcription verification for data in their laboratory notebooks. More serious still, the first test for which Iuorno failed contemporaneously to enter data in a laboratory notebook yielded a result falling outside prescribed limits. DuPont procedures and FDA regulations required her immediately to report this fact to her supervisor. Iuorno failed to report the problem to anyone; instead, she took it upon herself to retest the samples several days later, in further violation of DuPont procedures and FDA requirements regarding retesting. It was not until the day after this retesting that Iuorno entered any data pertaining to the questioned samples in a bound laboratory notebook. When her supervisor discovered the problem and asked Iuorno for an explanation, she stated that she had been under considerable pressure to finish her test assignments expeditiously.

In an effort to demonstrate that DuPont’s stated reason for terminating her was not these violations but rather a bias against her i-ace, national origin, or age, Iuorno submits that similarly situated employees, who did not belong to the same protected groups as she, received more favorable treatment when questions arose about their compliance with laboratory procedures. “A showing that similarly situated employees” falling outside the protected class “received more favorable treatment can ... serve as evidence that the employer’s proffered legitimate, nondiscriminatory reason for the adverse job action was a pretext” for unlawful discrimination, but only if the plaintiff shows that she was “ ‘similarly situated in all material respects’ ” to the individuals with whom she seeks to compare herself. Graham v. Long Island R.R., 230 F.3d 34, 39 (2d Cir.2000) (quoting Shumway v. United Parcel Serv., Inc., 118 F.3d 60, 64 (2d Cir.1997)); accord Norville v. Staten Island Univ. Hosp., 196 F.3d 89, 96 (2d Cir.1999). Iuorno fails to meet this standard.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Williams v. Mount Sinai Medical Center
859 F. Supp. 2d 625 (S.D. New York, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
129 F. App'x 637, Counsel Stack Legal Research, https://law.counselstack.com/opinion/iuorno-v-dupont-pharmaceuticals-co-ca2-2005.